1. 176: YAP/TAZ ACTIVATION IS A MECHANISM OF TUMOR PROGRESSION IN THE POORLY COHESIVE GASTRIC CANCER PHENOTYPE. (23rd April 2022) Authors: Sacco, M; Bencivenga, M; Torroni, L; Tomezzoli, A; Castelli, C; Alloggio, M; Verlato, G; Giacopuzzi, S; Iglesias, M; Pera, M; De Manzoni, G; Melisi, D Journal: Diseases of the esophagus Issue: Volume 35(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 25PFunctional inhibition of TGF-β in colorectal cancer cells and its interaction with AXL receptor. (23rd October 2018) Authors: Ciardiello, D; Martini, G; Matrone, N; Belli, V; Vitiello, P P; Cardone, C; Ciaramella, V; Barra, G; Poliero, L; Borrelli, C; Troiani, T; Melisi, D; Morgillo, F; Giunta, E F; De Falco, V; Ciardiello, F; Martinelli, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 66PDual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer. (1st October 2019) Authors: Ciardiello, D; Belli, V; Cardone, C; Vitiello, P P; Martini, G; Poliero, L; Borrelli, C; Arrichiello, G; Ciaramella, V; Matrone, N; Barra, G; De Falco, V; Giunta, E F; Morgillo, F; Troiani, T; Terminiello, M; Melisi, D; Ciardiello, F; Martinelli, E Journal: Annals of oncology Issue: Volume 30(2019)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 723PFirst-line (1L) full dose (f) and modified (m) FOLFIRINOX and gemcitabine+nab-paclitaxel (GN) treatment (tx) for metastatic pancreatic adenocarcinoma (mPAC) patients (pts) in routine clinical practice across Europe. (23rd October 2018) Authors: Taieb, J; Carrato, A; Westphalen, B; Melisi, D; Prager, G; Macarulla Mercade, T; Mellbring, Å B C; d'Esquermes, N; Ferreras, A; de Jong, F Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P-167Symptoms reported at initial diagnosis of (metastatic) pancreatic adenocarcinoma ([m]PAC) in routine clinical practice and variation in frequencies across Europe. (20th June 2018) Authors: Melisi, D; Westphalen, B; àMellbring, ; Carrato, A; Taieb, J; Prager, G; Macarulla Mercadé, T; Esquermes, N D´; Ferreras, A; de Jong, F Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PD-004Baseline characteristics and second-line treatment for metastatic pancreatic adenocarcinoma (mPAC) patients receiving first-line FOLFIRINOX, gemcitabine+nab-paclitaxel or gemcitabine-monotherapy in routine clinical practice across Europe. (20th June 2018) Authors: Prager, G; Mercadé, T Macarulla; àMellbring, ; Taieb, J; Carrato, A; Melisi, D; Westphalen, B; Esquermes, N D´; Ferreras, A; de Jong, F Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗